A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MA / Malignant ascites

[Related PubMed/MEDLINE]
Total Number of Papers: 32
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MA  (>> Co-occurring Abbreviation)
Long Form:   Malignant ascites
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Clinical Value of Positron Emission Tomography-Computed Tomography Combined with Ultrasound in Detection of Primary Tumors in Patients with Malignant Ascites. PET-CT
2019 Determination of kansuiphorin C and kansuinin A in rat feces using UFLC-MS/MS and its application in the comparative excretion study on normal and malignant ascites rats. KA, KPC
2019 Malignant ascites-derived exosomes promote peritoneal tumor cell dissemination and reveal a distinct miRNA signature in advanced gastric cancer. EMT, GC, PD
2019 Palliation of malignant ascites. i.p, QOL
2019 Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology. ---
2019 Tunneled Peritoneal Catheter Placement in Palliation of Malignant Ascites: A Study with Two Different Types of Catheters. THC, TPC
2018 Recruitment and significance of Th22 cells and Th17 cells in malignant ascites. CCR, HCC, Th
2018 Therapeutic Procedures for Malignant Ascites in a Palliative Care Outpatient Clinic. TC
2017 Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report. ---
10  2017 Clinical and biological effects of tumor-associated lymphocytes in the presence or absence of chemotherapy for malignant ascites in ovarian cancer patients. AAS, KPS, OC, OS, TALs, TTP
11  2017 Drainage of malignant ascites: patient selection and perspectives. PC, PRO, QOL
12  2017 Metabolomic characterization of experimental ovarian cancer ascitic fluid. VEGF
13  2016 Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation. RCC
14  2016 Efficacy and safety of ultrasound-guided continuous hyperthermic intraperitoneal perfusion chemotherapy for the treatment of malignant ascites: a midterm study of 36 patients. CHIPC, KPS
15  2015 A survey of treatment approaches of malignant ascites in Germany and Austria. GE, GYN, MO, PC, pts
16  2015 Exosomal miRNAs from Peritoneum Lavage Fluid as Potential Prognostic Biomarkers of Peritoneal Metastasis in Gastric Cancer. GC, PLF, qRT-PCR
17  2015 Hemodynamic Consequences of Malignant Ascites in Epithelial Ovarian Cancer Surgery*: A Prospective Substudy of a Randomized Controlled Trial. EOC, FFP
18  2015 Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. HIPEC
19  2015 Management of symptomatic ascites and post-operative lymphocysts with an easy-to-use, patient-controlled, vascular catheter. LCs
20  2015 Outpatient Intraperitoneal Catumaxomab Therapy for Malignant Ascites Related to Advanced Gynecologic Neoplasms. CATU, EpCAM, i.p, MBC, OS, PuFS
21  2015 Pancreatic cancer with malignant ascites: clinical features and outcomes. OS
22  2015 Quantum dot-based multiplexed imaging in malignant ascites: a new model for malignant ascites classification. QD
23  2014 A pilot study of combination intraperitoneal recombinant human endostatin and chemotherapy for refractory malignant ascites secondary to ovarian cancer. OC
24  2014 The clinical effects of dendritic cell vaccines combined with cytokine-induced killer cells intraperitoneal injected on patients with malignant ascites. CIK, DCR, GM-CSF, IFN-gamma, IL-10, MCP-1, RR, VEGF
25  2013 Malignant ascites: pathophysiology and treatment. HIPEC
26  2012 Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone. EpCAM, QOL
27  2011 Antagonism of VEGF by genetically engineered dendritic cells is essential to induce antitumor immunity against malignant ascites. DC, sFLT-1
28  2011 Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). EpCAM, FcgammaRs, i.p, TRAB
29  2010 Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. EpCAM, FcgammaR, i.p, trAb
30  2010 Malignant ascites symptom cluster in patients referred for paracentesis. QOL
31  1994 Total discrimination of peritoneal malignant ascites from cirrhosis- and hepatocarcinoma-associated ascites by assays of ascitic cholesterol and lactate dehydrogenase. LD
32  1993 Value of ascitic fluid ferritin in the differential diagnosis of malignant ascites. CLD, HCC, SAAG